Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.

Journal Article

VNP40101M is a novel alkylating agent that yields two reactive compounds (a chloroethylating species and methylisocyanate) and has demonstrated activity against a wide spectrum of tumor xenografts. VNP40101M was tested against an in vivo panel of five pediatric brain tumor xenografts at a dose of 18 mg/kg/day administered for 5 days. O-6-methylguanine-DNA methyltransferase (MGMT) levels of xenografts were assessed by Western blot analysis. Only one xenograft (GBM2), which lacked detectable MGMT expression, demonstrated an objective response to VNP40101M. VNP4010M antitumor activity was observed only in the absence of MGMT expression, with resistance to VNP4010M seen even with low MGMT expression.

Full Text

Duke Authors

Cited Authors

  • Keir, ST; Morton, CL; Billups, C; Smith, MA; Houghton, PJ; Gururangan, S

Published Date

  • September 2008

Published In

Volume / Issue

  • 51 / 3

Start / End Page

  • 439 - 441

PubMed ID

  • 18493996

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.21620

Language

  • eng

Conference Location

  • United States